• Zuhat Urakçı, Senar Ebinç, Zeynep Oruc, Ziya Kalkan, Muhammet Ali Kaplan, Mehmet Küçüköner, and Abdurrahman Işıkdoğan.
• Faculty of Medicine, Department of Medical Oncology, Dicle University, Diyarbakır, Turkey.
• Postgrad Med. 2024 Mar 1; 136 (2): 162168162-168.

ObjectivesIn this study, we aimed to investigate the causes of liver test abnormalities in newly diagnosed patients naive to anti-tumoral therapy.MethodThis study included a total of 490 patients with ALT levels > 5X ULN on liver function tests at the initial presentation to our clinic. Data from 247 (50.4%) patients diagnosed with cancer (cohort A) and 243 (49.6%) patients without cancer (cohort B) were compared with regard to the etiology of liver test abnormalities and the risk factors.ResultsThe most common etiological factor in cohort A was presence of liver metastasis (31.2%, n = 77). In the comparison of the two groups with regard to etiological factors; the rates of liver metastasis [31.2% vs 0%, (p < 0.001)], drug-induced liver toxicity [30/4% vs 19.8%, (p = 0.007)], pancreaticobiliary pathology [21.5% vs 14%, (p = 0.03)] and chronic viral hepatitis [14.2% vs 7.4%, (p = 0.02)] were higher in the cohort A. The rate of NAFLD was higher in the cohort B [6.9% vs 42.2% (p < 0.001).ConclusionIn our study, the most common cause of liver test abnormalities was the presence of liver metastasis in cohort A and NAFLD in cohort B.

26 keywords...

hide…